Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Capital Expenditures (2022 - 2024)

Zentalis Pharmaceuticals has reported Capital Expenditures over the past 3 years, most recently at $181000.0 for Q2 2024.

  • Quarterly results put Capital Expenditures at $181000.0 for Q2 2024, down 43.26% from a year ago — trailing twelve months through Mar 2025 was $181000.0 (down 70.95% YoY), and the annual figure for FY2024 was $221000.0, down 62.09%.
  • Capital Expenditures for Q2 2024 was $181000.0 at Zentalis Pharmaceuticals, up from $40000.0 in the prior quarter.
  • Over the last five years, Capital Expenditures for ZNTL hit a ceiling of $2.3 million in Q3 2022 and a floor of -$135000.0 in Q2 2022.
  • Median Capital Expenditures over the past 3 years was $173000.0 (2023), compared with a mean of $372444.4.
  • Peak annual rise in Capital Expenditures hit 336.3% in 2023, while the deepest fall reached 96.04% in 2023.
  • Zentalis Pharmaceuticals' Capital Expenditures stood at $160000.0 in 2022, then grew by 8.12% to $173000.0 in 2023, then grew by 4.62% to $181000.0 in 2024.
  • The last three reported values for Capital Expenditures were $181000.0 (Q2 2024), $40000.0 (Q1 2024), and $173000.0 (Q4 2023) per Business Quant data.